The pharmacologies of GLP-1 RAs and putative targeting in select brain regions implicated in the pathogenesis of the aforementioned mental disorders provides the compelling rationale for the reuporposing of GLP-1 RAs in the treatment and prevention of mental disorders. The gene discussed is GLP1R; the disease is psychiatric disorder.